Oncology Medical News about myelodysplastic syndromes

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Impact on survival of different treatments for myelodysplastic syndromes (MDS)
Leukemia Research, 06/19/09

Nachtkamp K et al. - With the exception of allo-SCT, MDS treatment was generally palliative. Recently, epigenetic treatment with demethylating agents proved to be the first therapy that can significantly prolong survival in patients with higher-risk MDS.

<< Previous
Extramedullary (EMP) relapse in unusual locations in multiple...

Next >>
A myeloproliferative disorder may hide another one

Prognostic molecular markers in myelodysplastic syndromes
Expert Review of Hematology, 10/22/09 Relevance Score: 68%

Hematopoiesis-related microRNA expression in myelodysplastic syndromes
Leukemia and Lymphoma, 11/06/09 Relevance Score: 67%

Clinical significance of Th1/Th2 ratio in patients with myelodysplastic syndrome
International Journal of Laboratory Hematology, 10/28/09 Relevance Score: 66%

Accelerated cellular senescence in myelodysplastic syndrome
Experimental Hematology, 10/22/09 Relevance Score: 66%

Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression
Blood, 10/09/09 Relevance Score: 66%